Literature DB >> 18698627

Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma.

Mervi Taskinen1, Annamari Ranki, Eero Pukkala, Leila Jeskanen, Ilkka Kaitila, Outi Mäkitie.   

Abstract

Cartilage-hair hypoplasia (CHH) is an autosomal recessive chondrodysplasia with short stature, sparse hair and defective cell-mediated immunity. It is caused by mutations in the RMRP (ribonuclease mitochondrial RNA processing) gene, encoding the RNA component of the ribonuclease complex RNase MRP. The aim of this study was to further elucidate the risk and spectrum of cancer in CHH. A cohort of 123 Finnish patients with CHH (51 males) was followed for malignancy through the Finnish Cancer Registry. The number of identified cancers was compared with expected numbers of cancer using population-based data to obtain standardized incidence ratios (SIR). Hospital records were reviewed for clinical data related to the malignancies. During the follow-up (2,365 person-years; mean 19.2 years), 14 cases of cancer were diagnosed in the CHH cohort (expected number 2.0; SIR 7.0, CI 3.8-12). Non-Hodgkin lymphoma was the most frequent cancer type (n = 9; SIR 90.2, CI 39.0-180) followed by squamous cell carcinoma (3), leukemia (1) and Hodgkin lymphoma (1). One tumor was not histologically classified. Nine of the 14 cancers were diagnosed in patients less than 45 years of age. In addition, ten patients had basal cell carcinoma of the skin (expected number 0.3; SIR 33.2, CI 16-61). Patients with CHH have significantly increased risk for developing non-Hodgkin lymphoma or basal cell carcinoma at early age; the overall prognosis is poor. The underlying pathogenetic mechanisms remain to be elucidated in future studies. Careful follow-up, extending beyond pediatric age, is warranted for early diagnosis of malignancies. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18698627     DOI: 10.1002/ajmg.a.32478

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  26 in total

Review 1.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  Ribosomopathies: human disorders of ribosome dysfunction.

Authors:  Anupama Narla; Benjamin L Ebert
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

3.  Global identification of new substrates for the yeast endoribonuclease, RNase mitochondrial RNA processing (MRP).

Authors:  Jason Aulds; Sara Wierzbicki; Adrian McNairn; Mark E Schmitt
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

Review 4.  The Evolution of the Ribosomal Protein-MDM2-p53 Pathway.

Authors:  Chad Deisenroth; Derek A Franklin; Yanping Zhang
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

Review 5.  RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance.

Authors:  Yong Liu; Chad Deisenroth; Yanping Zhang
Journal:  Trends Cancer       Date:  2016-04-04

6.  Autoimmune hypoparathyroidism in a 12-year-old girl with McKusick cartilage hair hypoplasia.

Authors:  Justine Bacchetta; Bruno Ranchin; Anne Sophie Brunet; Raymonde Bouvier; Agnès Duquesne; Patrick Edery; Nicole Fabien; Noël Peretti
Journal:  Pediatr Nephrol       Date:  2009-07-22       Impact factor: 3.714

Review 7.  Neutropenia in primary immunodeficiency.

Authors:  Robert Sokolic
Journal:  Curr Opin Hematol       Date:  2013-01       Impact factor: 3.284

8.  Variable phenotype of severe immunodeficiencies associated with RMRP gene mutations.

Authors:  Winnie Ip; H Bobby Gaspar; Robert Kleta; Estelle Chanudet; Chiara Bacchelli; Alison Pitts; Zohreh Nademi; E Graham Davies; Mary A Slatter; Persis Amrolia; Kanchan Rao; Paul Veys; Andrew R Gennery; Waseem Qasim
Journal:  J Clin Immunol       Date:  2015-02-08       Impact factor: 8.317

Review 9.  Educational paper: syndromic forms of primary immunodeficiency.

Authors:  Rogier Kersseboom; Alice Brooks; Corry Weemaes
Journal:  Eur J Pediatr       Date:  2011-02-22       Impact factor: 3.183

10.  Viperin mRNA is a novel target for the human RNase MRP/RNase P endoribonuclease.

Authors:  Sandy Mattijssen; Ella R Hinson; Carla Onnekink; Pia Hermanns; Bernhard Zabel; Peter Cresswell; Ger J M Pruijn
Journal:  Cell Mol Life Sci       Date:  2010-10-30       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.